Manuscripts and Publications

Filters: Keyword is Female and Author is Martinez, Fernando J  [Clear All Filters]
2014
O'Neal WK, Anderson W, Basta PV, Carretta EE, Doerschuk CM, R Barr G, Bleecker ER, Christenson SA, Curtis JL, Han MK et al..  2014.  Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study.. J Transl Med. 12:9.
Couper D, LaVange LM, Han ML, R Barr G, Bleecker E, Hoffman EA, Kanner R, Kleerup E, Martinez FJ, Woodruff PG et al..  2014.  Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS).. Thorax. 69(5):491-4.
2015
Boes JL, Hoff BA, Bule M, Johnson TD, Rehemtulla A, Chamberlain R, Hoffman EA, Kazerooni EA, Martinez FJ, Han MK et al..  2015.  Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS).. Acad Radiol. 22(2):186-94.
2016
Martinez CH, Diaz AA, Parulekar AD, Rennard SI, Kanner RE, Hansel NN, Couper D, Holm KE, Hoth KF, Curtis JL et al..  2016.  Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts.. Chest. 149(4):927-35.
Woodruff PG, R Barr G, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE et al..  2016.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.. N Engl J Med. 374(19):1811-21.
2017
Martinez CH, Diaz AA, Meldrum C, Curtis JL, Cooper CB, Pirozzi C, Kanner RE, Paine R, Woodruff PG, Bleecker ER et al..  2017.  Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS.. Am J Respir Crit Care Med. 195(4):464-472.
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, R Barr G et al..  2017.  Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(12):956-967.
Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, R Barr G et al..  2017.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.. Am J Respir Crit Care Med. 195(4):473-481.
Han MK, Quibrera PM, Carretta EE, R Barr G, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL et al..  2017.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(8):619-626.
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
Anderson WH, Ha JWook, Couper DJ, O'Neal WK, R Barr G, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, M Drummond B et al..  2017.  Variability in objective and subjective measures affects baseline values in studies of patients with COPD.. PLoS One. 12(9):e0184606.
2018
Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, Woo J, J Wells M, Labaki WW, Doerschuk CM et al..  2018.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS.. Ann Am Thorac Soc. 15(6):710-717.
Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, Criner G, Galbán CJ, Ross BD, Hoffman EA et al..  2018.  Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.. Am J Respir Crit Care Med. 198(2):265-267.
Bhatt SP, Nath HP, Kim Y-I, Ramachandran R, Watts JR, Terry NLJ, Sonavane S, Deshmane SP, Woodruff PG, Oelsner EC et al..  2018.  Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort.. Respir Res. 19(1):257.
J Wells M, Parker MM, Oster RA, Bowler RP, Dransfield MT, Bhatt SP, Cho MH, Kim V, Curtis JL, Martinez FJ et al..  2018.  Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene.. JCI Insight. 3(22)
Li X, Ortega VE, Ampleford EJ, R Barr G, Christenson SA, Cooper CB, Couper D, Dransfield MT, Han MLan K, Hansel NN et al..  2018.  Genome-wide association study of lung function and clinical implication in heavy smokers.. BMC Med Genet. 19(1):134.
Pirozzi CS, Gu T, Quibrera PM, Carretta EE, Han MK, Murray S, Cooper CB, Tashkin DP, Kleerup EC, Barjaktarevic I et al..  2018.  Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.. Respir Res. 19(1):223.
Smith BM, Traboulsi H, Austin JHM, Manichaikul A, Hoffman EA, Bleecker ER, Cardoso WV, Cooper C, Couper DJ, Dashnaw SM et al..  2018.  Human airway branch variation and chronic obstructive pulmonary disease.. Proc Natl Acad Sci U S A. 115(5):E974-E981.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, R Barr G, Bleecker E, Cooper CB, Couper D et al..  2018.  Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Respir Res. 19(1):178.
Putcha N, Paul GG, Azar A, Wise RA, O'Neal WK, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, M Drummond B et al..  2018.  Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS.. PLoS One. 13(4):e0194924.
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
2019
Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, R Barr G, Bleecker ER et al..  2019.  An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.. J Clin Invest. 129(1):169-181.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Oelsner EC, Ortega VE, Smith BM, Nguyen JN, Manichaikul AW, Hoffman EA, Guo X, Taylor KD, Woodruff PG, Couper DJ et al..  2019.  A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography.. Am J Respir Crit Care Med. 200(6):721-731.

Pages